Last updated: June 3, 2026
TRAVASOL 5.5% IN PLASTIC CONTAINER Suppliers: Who Manufactures and Sources This Injectable Amino Acid Solution?
Suppliers for TRAVASOL 5.5% in plastic container are best mapped at two levels: primary marketing/holding entity and manufacturing sites (which determine downstream supply and import flows). TRAVASOL is an established intravenous amino-acid infusion used in parenteral nutrition; the supplier set depends on the country market and container presentation (“plastic container” can map to different packaging configurations by region and distributor).
Who is the manufacturer of TRAVASOL 5.5% in a plastic container?
Manufacturer identification is market-specific. In the EU/UK supply chain, TRAVASOL is typically supplied under the marketing authorization held by a European pharma entity and produced by one or more contracted sterile manufacturing facilities. The “plastic container” presentation ties the product to a specific packaging and sterile fill-finish line, which can change by country lot release.
What entities commonly sit in the TRAVASOL supply chain?
In practice, the supplier ecosystem for TRAVASOL products is organized as:
- Marketing authorization holder (MAH): sets label, batch release responsibility in the local territory, and coordinates regulatory submissions.
- Contract manufacturers / packagers: perform sterile manufacture, sterile filtration/filling, and packaging into plastic containers.
- Wholesalers and hospital distributors: do not change the drug substance manufacturing, but control availability via tender and distribution agreements.
- Parallel importers (where applicable): source from other EU member states and re-import into the local market.
Which companies supply TRAVASOL 5.5% to hospitals and distributors?
Retail/hospital availability depends on local procurement channels:
- Authorized wholesalers: supply through normal distribution networks.
- Tender-based supply: common in hospital systems, with supplier lists that track specific package formats, including plastic container configurations.
- Regional distributors: some territories rely on a small number of listed distributors for hospital tenders and formulary placement.
What determines supplier eligibility for TRAVASOL plastic containers?
- GMP batch release to the destination market
- Correct presentation and strength mapping (5.5% amino acids)
- Packaging integrity and shelf-life approvals for the plastic container configuration
- Regulatory labeling requirements (language and local safety information)
What suppliers provide TRAVASOL 5.5% internationally, and how do imports work?
Cross-border supply is typically handled via:
- Direct distribution from MAH-appointed distributors
- EU/UK wholesaler importers that buy in-region and ship to contracting customers
- Parallel trade where permitted, using pharmacy-grade supply chains and local authorization status
Which supply risk factors affect continuity?
- Single-site fill-finish capacity for plastic containers
- Sterile line maintenance schedules
- Packaging material lead times for the plastic container component and closure system
- Regulatory lot-release bottlenecks
Which wholesalers/distributors are most likely to list TRAVASOL 5.5% in plastic containers?
Wholesaler lists differ by country. In mature markets, the drug is usually stocked by:
- National wholesale distributors
- Hospital-group purchasing platforms that pre-qualify products by NDC/GTIN and presentation
- Temperature-controlled logistics providers for parenteral nutrition SKUs
How to interpret “supplier” in tenders
Tenders typically name:
- Manufacturer (to document GMP origin)
- Marketing authorization holder (regulatory accountability)
- Tender supplier/distributor (who delivers to the hospital)
What does “plastic container” imply for TRAVASOL supply versus glass vials?
The plastic container presentation is a supply constraint in itself:
- It requires specific aseptic filling systems and container-closure integrity.
- It uses container materials and sealing systems that can differ from alternative presentations (e.g., different container formats or packaging sizes).
- It can impact allocation during high demand if the plastic-container line has limited capacity.
Key Takeaways
- TRAVASOL 5.5% in plastic containers is supplied through a chain dominated by the marketing authorization holder and one or more GMP manufacturing sites that support the plastic-container presentation.
- “Supplier” in procurement contexts usually refers to the tender distributor, while “manufacturer” refers to the GMP sterile production and packaging site.
- Plastic-container format ties supply to specific fill-finish and packaging line capacity, so availability can shift by region even when the active product is unchanged.
FAQs
-
How do I confirm the true manufacturing site for TRAVASOL 5.5% plastic containers?
Check the local batch release labeling and certificate-of-analysis references on the delivered pack, which tie to the GMP site.
-
Do TRAVASOL 5.5% suppliers change during shortages?
Supply continuity can shift via parallel importation or alternate distributors if the manufacturing supply is fixed and allocations occur.
-
Can TRAVASOL 5.5% in plastic containers be substituted with another presentation?
Substitution depends on identical concentration, container configuration, and clinical equivalence under local formulary and procurement rules.
-
What causes delays in TRAVASOL plastic-container deliveries?
Common drivers are GMP lot release timing and plastic container component lead times.
-
Are TRAVASOL suppliers the same across EU countries?
Not necessarily. MAH and distributor structures are often territory-specific even if the underlying product and manufacturing chain are linked.
References
- (No citable source was provided in the prompt and no product-specific supplier dataset was supplied.)
